Dihydroartemisinin is potential therapeutics for treating late-stage CRC by targeting the elevated c-Myc level

Currently, no frontline treatment is effective for the late-stage colorectal cancer (CRC). Understanding the molecular differences in different stages of CRC can help us to identify the critical therapeutic targets for designing therapeutic strategy. Our data show that c-Myc protein is highly expres...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xianjing, Fatima, Sarwat, Chen, Minting, Huang, Tao, Chen, Yuen Wa, Gong, Ruihong, Wong, Hoi Leong Xavier, Yu, Rongmin, Song, Liyan, Kwan, Hiu Yee, Bian, Zhaoxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571272/
https://www.ncbi.nlm.nih.gov/pubmed/34741022
http://dx.doi.org/10.1038/s41419-021-04247-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571272/
https://www.ncbi.nlm.nih.gov/pubmed/34741022
http://dx.doi.org/10.1038/s41419-021-04247-w

Ejemplares similares